Fulcrum Therapeutics develops small molecule drugs designed to regulate gene expression for the treatment of genetically defined rare diseases. The company focuses its clinical efforts on hematology indications, including therapies intended to elevate fetal hemoglobin levels in patients with sickle cell disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -17.7 | — |
| Q2 2025 | 0 | — | -17.3 | — |
| Q3 2025 | 0 | — | -19.6 | — |
| Q4 2025 | 0 | — | -20.3 | — |
| Q1 2026 | 0 | — | -18.9 | — |
| Q2 2026 | 0 | — | -26.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: C&F Financial Corporation (CFFI), General Purpose Acquisition Corp. (GPAC), RCM Technologies, Inc. (RCMT), Hall Chadwick Acquisition Corp. (HCAC), Alico, Inc. (ALCO), Iron Horse Acquisitions Corp. II (IRHO)